Moderna Free Cash Flow (FCF) History (MRNA)
Moderna reported −$2.06B in free cash flow for fiscal 2025, an increase of $1.99B from the previous fiscal year, with a free cash flow margin of −106.22%.
View full Moderna company overviewModerna free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$2.06B | $1.99B | — | −106.22% |
| 2024 | 2024-12-31 | −$4.05B | −$230.0M | — | −125.31% |
| 2023 | 2023-12-31 | −$3.83B | −$8.41B | — | −55.86% |
| 2022 | 2022-12-31 | $4.58B | −$8.76B | −65.65% | +23.78% |
| 2021 | 2021-12-31 | $13.34B | $11.38B | +580.76% | +72.20% |
| 2020 | 2020-12-31 | $1.96B | $2.45B | — | +243.96% |
| 2019 | 2019-12-31 | −$491.0M | −$54.4M | — | −815.49% |
| 2018 | 2018-12-31 | −$436.6M | −$46.7M | — | −323.27% |
| 2017 | 2017-12-31 | −$389.9M | −$423.5M | — | −189.43% |
| 2016 | 2016-12-31 | $33.6M | — | — | +30.99% |
Moderna quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$563.0M | $359.0M | — | −388.28% |
| Q1 2026 | 2026-03-31 | −$692.0M | $462.0M | — | −177.89% |
| Q4 2025 | 2025-12-31 | $891.0M | $588.0M | +194.06% | +131.42% |
| Q3 2025 | 2025-09-30 | −$880.0M | $837.0M | — | −86.61% |
| Q2 2025 | 2025-06-30 | −$922.0M | $534.0M | — | −649.30% |
| Q1 2025 | 2025-03-31 | −$1.15B | $31.0M | — | −1068.52% |
| Q4 2024 | 2024-12-31 | $303.0M | −$99.0M | −24.63% | +31.37% |
| Q3 2024 | 2024-09-30 | −$1.72B | $23.0M | — | −92.21% |
| Q2 2024 | 2024-06-30 | −$1.46B | −$307.0M | — | −604.15% |
| Q1 2024 | 2024-03-31 | −$1.19B | $153.0M | — | −709.58% |
| Q4 2023 | 2023-12-31 | $402.0M | −$1.17B | −74.39% | +14.30% |
| Q3 2023 | 2023-09-30 | −$1.74B | −$1.90B | — | −95.03% |
| Q2 2023 | 2023-06-30 | −$1.15B | −$1.37B | — | −334.01% |
| Q1 2023 | 2023-03-31 | −$1.34B | −$3.97B | — | −71.86% |
| Q4 2022 | 2022-12-31 | $1.57B | −$1.62B | −50.78% | +30.88% |
| Q3 2022 | 2022-09-30 | $163.0M | −$3.01B | −94.87% | +4.85% |
| Q2 2022 | 2022-06-30 | $217.0M | −$3.82B | −94.62% | +4.57% |
| Q1 2022 | 2022-03-31 | $2.63B | −$305.0M | −10.39% | +43.37% |
| Q4 2021 | 2021-12-31 | $3.19B | $1.95B | +157.26% | +44.24% |
| Q3 2021 | 2021-09-30 | $3.18B | $2.30B | +263.50% | +63.94% |
| Q2 2021 | 2021-06-30 | $4.03B | $4.08B | — | +92.63% |
| Q1 2021 | 2021-03-31 | $2.94B | $3.05B | — | +151.57% |
| Q4 2020 | 2020-12-31 | $1.24B | $1.35B | — | +217.16% |
| Q3 2020 | 2020-09-30 | $874.0M | $987.8M | — | +556.69% |
| Q2 2020 | 2020-06-30 | −$43.0M | $76.2M | — | −64.18% |
| Q1 2020 | 2020-03-31 | −$112.0M | $39.9M | — | −1400.00% |
| Q4 2019 | 2019-12-31 | −$106.2M | −$1.5M | — | −755.33% |
| Q3 2019 | 2019-09-30 | −$113.8M | −$7.5M | — | −667.63% |
| Q2 2019 | 2019-06-30 | −$119.2M | −$36.8M | — | −910.88% |
| Q1 2019 | 2019-03-31 | −$151.9M | −$8.6M | — | −947.66% |
| Q4 2018 | 2018-12-31 | −$104.7M | — | — | −295.47% |
| Q3 2018 | 2018-09-30 | −$106.4M | — | — | −254.69% |
| Q2 2018 | 2018-06-30 | −$82.3M | — | — | −285.36% |
| Q1 2018 | 2018-03-31 | −$143.3M | — | — | −493.45% |
Moderna free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $1.96B to −$2.06B, a net decrease of $4.02B. Moderna's latest reported quarter, Q2 2026, generated −$563.0M in free cash flow, an increase of $359.0M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Moderna filings at SEC.gov ↗